FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366834167> ?p ?o ?g. }

• W4366834167 endingPage "104562" @default.
• W4366834167 startingPage "104562" @default.
• W4366834167 abstract "This analysis evaluated the immune response to the two-dose, heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen, administered 56-days apart, from multiple African sites based on results from one analytic laboratory.Immunogenicity across three trials (EBL2002, EBL2004/PREVAC, EBL3001) conducted in East and West Africa is summarised. Vaccine-induced Ebola glycoprotein-binding antibody concentrations were analysed by Q2 Solutions laboratory at baseline, 21 days (EBL2002 and EBL3001) or 28 days (EBL2004) post-dose 2 (regimen completion), and 12 months post-dose 1 using the validated Filovirus Animal Nonclinical Group Ebola glycoprotein enzyme-linked immunosorbent assay (ELISA). Responders were defined as those with a >2.5-fold increase from baseline or the lower limit of quantification (LLOQ) if <LLOQ at baseline.At 21 or 28 (21/28) days post-dose 2, the geometric mean concentration (GMC) range was 3810-7518 ELISA units (EU)/mL (percent responders: ≥98%) in adults, 9929-13532 EU/mL (≥98%) in adolescents aged 12-17 years, 10,212-17388 EU/mL (≥99%) in older children, and 22,568-25111 EU/mL (≥98%) in younger children. When stratified by country, GMCs at 21/28 days post-dose 2 were generally similar among adults and within paediatric cohorts (percent responders: 95%-100%). At month 12, GMC range was 259-437 EU/mL (percent responders: 49%-88%) in adults and 386-1139 EU/mL (70%-100%) in paediatric participants.Based on data from a single laboratory using a single validated assay, Ad26.ZEBOV, MVA-BN-Filo induced a strong humoral immune response, with ≥95% of participants across countries classified as responders at 21/28 days post-dose 2 (regimen completion), regardless of age.Janssen Vaccines & Prevention BV; Innovative Medicines Initiative." @default.
• W4366834167 created "2023-04-25" @default.
• W4366834167 creator A5004612991 @default.
• W4366834167 creator A5008208199 @default.
• W4366834167 creator A5008312486 @default.
• W4366834167 creator A5015870296 @default.
• W4366834167 creator A5019288275 @default.
• W4366834167 creator A5021703028 @default.
• W4366834167 creator A5022077216 @default.
• W4366834167 creator A5027270405 @default.
• W4366834167 creator A5030863765 @default.
• W4366834167 creator A5035818066 @default.
• W4366834167 creator A5037653154 @default.
• W4366834167 creator A5038550572 @default.
• W4366834167 creator A5040533373 @default.
• W4366834167 creator A5042440987 @default.
• W4366834167 creator A5043033469 @default.
• W4366834167 creator A5043150960 @default.
• W4366834167 creator A5043524877 @default.
• W4366834167 creator A5054399246 @default.
• W4366834167 creator A5054654748 @default.
• W4366834167 creator A5057901946 @default.
• W4366834167 creator A5063615518 @default.
• W4366834167 creator A5064321842 @default.
• W4366834167 creator A5070877757 @default.
• W4366834167 creator A5078709209 @default.
• W4366834167 creator A5079631288 @default.
• W4366834167 creator A5085743141 @default.
• W4366834167 creator A5088554079 @default.
• W4366834167 date "2023-05-01" @default.
• W4366834167 modified "2023-10-08" @default.
• W4366834167 title "Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory" @default.
• W4366834167 cites W2009400942 @default.
• W4366834167 cites W2034653667 @default.
• W4366834167 cites W2065076563 @default.
• W4366834167 cites W2083259574 @default.
• W4366834167 cites W2102327056 @default.
• W4366834167 cites W2122088182 @default.
• W4366834167 cites W2169112422 @default.
• W4366834167 cites W2409436874 @default.
• W4366834167 cites W2621596527 @default.
• W4366834167 cites W2803143011 @default.
• W4366834167 cites W2939751461 @default.
• W4366834167 cites W3112632192 @default.
• W4366834167 cites W3114648574 @default.
• W4366834167 cites W3199739238 @default.
• W4366834167 cites W3200905140 @default.
• W4366834167 cites W3209728196 @default.
• W4366834167 cites W4206655662 @default.
• W4366834167 cites W4226020952 @default.
• W4366834167 cites W4306907354 @default.
• W4366834167 cites W4311448090 @default.
• W4366834167 doi "https://doi.org/10.1016/j.ebiom.2023.104562" @default.
• W4366834167 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37099841" @default.
• W4366834167 hasPublicationYear "2023" @default.
• W4366834167 type Work @default.
• W4366834167 citedByCount "0" @default.
• W4366834167 crossrefType "journal-article" @default.
• W4366834167 hasAuthorship W4366834167A5004612991 @default.
• W4366834167 hasAuthorship W4366834167A5008208199 @default.
• W4366834167 hasAuthorship W4366834167A5008312486 @default.
• W4366834167 hasAuthorship W4366834167A5015870296 @default.
• W4366834167 hasAuthorship W4366834167A5019288275 @default.
• W4366834167 hasAuthorship W4366834167A5021703028 @default.
• W4366834167 hasAuthorship W4366834167A5022077216 @default.
• W4366834167 hasAuthorship W4366834167A5027270405 @default.
• W4366834167 hasAuthorship W4366834167A5030863765 @default.
• W4366834167 hasAuthorship W4366834167A5035818066 @default.
• W4366834167 hasAuthorship W4366834167A5037653154 @default.
• W4366834167 hasAuthorship W4366834167A5038550572 @default.
• W4366834167 hasAuthorship W4366834167A5040533373 @default.
• W4366834167 hasAuthorship W4366834167A5042440987 @default.
• W4366834167 hasAuthorship W4366834167A5043033469 @default.
• W4366834167 hasAuthorship W4366834167A5043150960 @default.
• W4366834167 hasAuthorship W4366834167A5043524877 @default.
• W4366834167 hasAuthorship W4366834167A5054399246 @default.
• W4366834167 hasAuthorship W4366834167A5054654748 @default.
• W4366834167 hasAuthorship W4366834167A5057901946 @default.
• W4366834167 hasAuthorship W4366834167A5063615518 @default.
• W4366834167 hasAuthorship W4366834167A5064321842 @default.
• W4366834167 hasAuthorship W4366834167A5070877757 @default.
• W4366834167 hasAuthorship W4366834167A5078709209 @default.
• W4366834167 hasAuthorship W4366834167A5079631288 @default.
• W4366834167 hasAuthorship W4366834167A5085743141 @default.
• W4366834167 hasAuthorship W4366834167A5088554079 @default.
• W4366834167 hasBestOaLocation W43668341671 @default.
• W4366834167 hasConcept C126322002 @default.
• W4366834167 hasConcept C159047783 @default.
• W4366834167 hasConcept C203014093 @default.
• W4366834167 hasConcept C2522874641 @default.
• W4366834167 hasConcept C2777469322 @default.
• W4366834167 hasConcept C2778933410 @default.
• W4366834167 hasConcept C2780868878 @default.
• W4366834167 hasConcept C2781413609 @default.
• W4366834167 hasConcept C71924100 @default.
• W4366834167 hasConcept C8891405 @default.
• W4366834167 hasConceptScore W4366834167C126322002 @default.
• W4366834167 hasConceptScore W4366834167C159047783 @default.

• next